Collectively, these findings highlight the importance of the information gathered from the crystal structure and may serve as the basis for the identification of new compounds, such as peptidomimetics, that may either selectively stabilize or disrupt the IP/PDZ1 interaction, with the ultimate goal of designing new therapeutic modalities for the treatment of some of the cardiovascular disease etiologies in which prostacyclin and its receptor, the IP, are most widely implicated. Here, PTGIR is linked to cardiovascular disorder.